drugset / Trial / NCT00348764

ESGVS: Sclerotherapy With Lauromacrogol

NCT00348764

Phase 3 Completed 150 enrolled University Hospital, Grenoble
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy and the tolerance of echoguided sclerotherapy using Lauromacrogol 400 foam for the treatment of Great Saphenous Vein (GSV) insufficiency. A comparative study of 3% versus 1% Lauromacrogol 400 foam.

Timeline

Start
2004-03
Primary completion
Completion
2006-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Polidocanol Other / unclassified 1 % Other
Subject Polidocanol Other / unclassified 3 % Other

Indications